Novartis raises 2026 core operating income outlook to flat to low-single-digit growth
- Novartis raised its 2026 core operating income outlook to flat to low-single-digit growth at constant currencies, from a low-single-digit decline.
- Net sales remain forecast to grow by a low-single-digit percentage at constant currencies.
- Third-quarter core operating income rose 10% at constant currencies to USD 6.04 billion; core margin reached 41.6%.
- Quarterly sales increased 4% at constant currencies to USD 14.52 billion, driven by priority brands and launches.
- The group reaffirmed 5%-6% sales CAGR for 2025-2030, with mid-single-digit long-term growth, both at constant currencies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.